Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose tumor has been confirmed to have a specific genetic change called MTAP loss
- People who are 18 years of age or older at the time of signing the study consent form
- People whose cancer has gotten worse, has not responded well enough to, or who could not tolerate the standard treatment — or for whom no standard treatment exists, or the doctor has decided standard treatment is not appropriate
- People who are able to swallow tablets
- People whose liver, kidneys, and other organs are functioning well enough based on blood tests done at a local lab
- People who have a negative pregnancy blood test at the screening visit
- People who have a performance status score of 0 or 1 on a standard scale (meaning they are fully active or have only minor limitations in physical activity)
- People whose cancer can be measured on scans using standard criteria (called RECIST v1.1), or people with a specific type of brain tumor (glioblastoma, IDH-wildtype) where scans show the disease has come back or gotten worse
- People with glioblastoma who score 70 or higher on a separate activity scale used for brain tumor patients (called the Karnofsky scale)
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who have digestive system problems that could affect how the study drug is absorbed into the body
- People who have an active infection currently being treated with medication
- People who have previously been treated with a type of drug called a PRMT5 inhibitor or a MAT2A inhibitor
- People joining the combination therapy part of the study who have previously been treated with a type of drug called a CDK4/6 inhibitor
- People with significant heart or blood vessel disease
- People with another ongoing or past illness that could affect their safety during the trial, make it hard to assess the study results, or affect their ability to follow the study requirements (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tab Cooney, MD, Tango Therapeutics, Inc.
Phone: (857) 320-4899
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1 Maximum Tolerated Dose; Phase 2 Anti-neoplastic Activity Single Agent; Phase 2 Anti-neoplastic Activity Combination Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.